title: N-palmitoyl-ethanolamine (PEA) induces peripheral antinociceptive effect by ATP-sensitive K+-channel activation.
abstract: Although the antinociceptive effects of N-palmitoyl-ethanolamine (PEA) were first characterized nearly 50 years ago, the identity of the mechanism that mediates these actions has not been elucidated. The present study investigated the contribution of K(+) channels on peripheral antinociception induced by the CB(2) agonist PEA. Nociceptive thresholds to mechanical paw stimulation of Wistar rats treated with intraplantar prostaglandin E(2) to induce hyperalgesia were measured, and other agents were also given by local injection. PEA (5, 10, and 20 µg/paw) elicited a local peripheral antinociceptive effect. This effect was antagonized by glibenclamide, a selective blocker of ATP-sensitive K(+) channels (20, 40, and 80 µg/paw). In addition, neither the voltage-dependent K(+) channel-specific blocker tetraethylammonium (30 µg/paw) nor the small and large conductance blockers of Ca(2+)-activated K(+) channels, dequalinium (50 µg/paw) and paxilline (20 µg/paw), respectively, were able to block the local antinociceptive effect of PEA. These results indicate that the activation of ATP-sensitive K(+) channels could be the mechanism that induces peripheral antinociception by PEA and that voltage-dependent K(+) channels and small and large conductance Ca(2+)-activated K(+) channels do not appear to be involved in this mechanism.
authors.affiliation: Department of Pharmacology, Institute of Biological Sciences (ICB), Federal University of Minas Gerais, Brazil.
authors.forename: Thiago Roberto Lima
authors.initials: TR
authors.lastname: Romero
authors.forename: Igor Dimitri Gama
authors.initials: ID
authors.lastname: Duarte
mesh_terms: D000577:Amides; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D003868:Dequalinium / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids; D004983:Ethanolamines; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology; D006930:Hyperalgesia / Q000188:drug therapy* / Q000503:physiopathology; D007211:Indoles / Q000494:pharmacology; D054086:KATP Channels / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D010169:Palmitic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000577:Amides; D000700:Analgesics; D063388:Endocannabinoids; D004983:Ethanolamines; D007211:Indoles; D054086:KATP Channels; D010169:Palmitic Acids; C048220:paxilline; C005958:palmidrol; D003868:Dequalinium; D015232:Dinoprostone; D005905:Glyburide